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a b s t r a c t 
Currently, drug abuse and addiction represent a global public health concern with about 13.6 million peo- 
ple using illicit drugs in the USA alone. Substance abuse intervenes in normal brain functioning, causing 
alterations in memory, behavior and neuronal physiology. Although many studies have been conducted to 
elucidate the mode of action of different drugs, the heterogeneous modes of drug intake led to a complicated 
proﬁle of drug-induced brain changes involving neurotoxicity and addiction. Given the complex interplay 
of genes and proteins in mediating these effects, neuroproteomics analysis has been considered among the 
methods of choice to complement what has already been discovered and to create targeted therapies. In this 
review, we will focus on three drugs, namely cocaine, methamphetamine (METH) and 3,4-methylenedioxy- 
N-methylamphetamine (MDMA). In the context of neuroproteomics, these drugs have been extensively 
studied by utilizing different experimental models, including primate and non-primate animals along with 
postmortem human samples. Even though there are many variations in the results, these drugs were shown 
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to employ common pathways in eliciting their effects. Neuroproteomics analysis of these drugs has led to 
the identiﬁcation of differentially expressed proteins involved in metabolism, oxidative stress, cell signal- 
ing, cytoskeleton, cell death and synaptic plasticity. Finally, this work will discuss recent ﬁndings from our 
laboratory by looking at a model of chronic methamphetamine abuse and its effect on different brain regions. 
c © 2014 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license 
( http: // creativecommons.org / licenses / by-nc-nd / 3.0 / ). 
1. Introduction 
1.1. Drug abuse and addiction 
Nowadays, drug abuse and addiction are among the prominent 
public health concerns, with a staggering number of 23.9 million peo- 
ple using illicit drugs and 4.5 million dependent on them in the USA 
alone [ 160 ]. Furthermore, there are only a few pharmacologic thera- 
pies that are speciﬁc for drug abuse and addiction [ 161 ]. Substances 
of addiction highly inﬂuence brain neurotransmissions and amplify 
the severity of medical conditions, such as diabetes and cardiovas- 
cular diseases [ 1 ]. Drug abuse, for instance, intervenes with normal 
brain networking and causes severe alterations in behavior, memory 
and neural cell life [ 2 ] and may even cause neuronal cell death [ 3 ]. 
This is why it is essential to understand the complex mechanisms 
through which every drug inaugurates its effect on a broad spectrum 
of cell signaling pathways and proteins, and this is where proteomics 
come into play. Addiction is deﬁned as a brain pathology provoked by 
complex processes that include physiological changes in certain brain 
regions such as the hippocampus, ventral tegmental area, nucleus ac- 
cumbens (NAc), and prefrontal cortex [ 4 ]. Interestingly, the effects of 
drug abuse were shown to be similar to those of traumatic brain injury 
(TBI). Lange et al. assessed the cognitive measures of verbal and visual 
memory and executive functioning abilities among 104 patients with 
mild TBI compared to 104 drug-abusers, and it was determined that 
there were no apparent differences among those two groups [ 5 ]. In 
this paper, we discuss recent updates in the ﬁelds of neuroproteomics 
in drug abuse followed by a brief discussion of our own lab ﬁndings 
of a model of chronic methamphetamine (METH) abuse and its ef- 
fect on different brain regions. The search criteria for the literature 
review included a PubMed search for the term “Neuroproteomics”
along with the different drug names. Only the most recent neuropro- 
teomics studies were taken into account and discussed in this paper. 
1.2. Proteomics 
Proteomics is an analytical approach enabling the analysis of pro- 
teins encoded by the genome of an organism [ 6 ]. A unit gene can 
generate several proteins via DNA processes such as transcription 
and translation. Proteomic analysis was introduced because the cor- 
relation between mRNA and protein levels proved insufﬁcient in 
studying protein expression levels from mRNA data [ 7 ]. Proteomic 
approaches can be further divided into four categories: ‘interac- 
tion proteomics ’ , ‘expression proteomics ’ , ‘structural proteomics ’ and 
‘functional proteomics ’ [ 8 ]. 
Proteomic studies fundamentally enable the identiﬁcation and 
quantiﬁcation of hundreds of proteins, thereby facilitating the global 
analysis of the function, variation, conﬁguration and dynamics (lo- 
calization, interaction and post-translational modiﬁcations) of pro- 
teins [ 9 ]. Thus, a proteomic study is ideal to characterize the cellular 
and molecular mechanisms of neuropsychiatric maladies, including 
drug abuse and addiction [ 2 ]. Herein, proteomic analysis reveals the 
pathophysiological routes involved [ 10 ] and unravels the behavioral 
alterations associated with these disorders [ 11 ]. Furthermore, drug 
response in addicts can be predicted and a therapeutic scheme can be 
prescribed and monitored according to the observed changes in the 
protein expression in humans and animal models, through proteomic 
analysis [ 12 ]. 
Proteomes include over 13 million distinct proteins in all species 
and over two million distinct proteins in humans alone [ 9 ]. Clinical 
applications of proteomics involves assessing the proteins in tissues, 
cells and body ﬂuids, including “human plasma, serum, urine, cere- 
brospinal ﬂuid, nipple aspirate ﬂuid, ductal lavage, amniotic ﬂuid, 
bile, lymph, breast milk, mucus, pleural ﬂuid, saliva and tears” [ 13 ]. 
Rapid advancements in proteomic research primarily hinges on the 
enhanced sensitivity of mass spectrometry (MS), bioinformatics, sys- 
tems biology and genomic sequence data acquisition [ 14 ]. 
1.3. Proteomic limitations in neuropsychiatry 
A proteomic study is currently challenged by a number of analyt- 
ical limitations, making proteomic-based studies far more complex 
than genomic-based ones [ 15 ]. One limitation is that in brain tis- 
sues, as in other types of tissues and cell lines, it is quite difﬁcult to 
associate mRNA expression with protein translation [ 16 , 17 ]. In addi- 
tion, few high-concentration proteins dominate each type of tissues, 
making the analysis of the low-abundant proteins challenging [ 18 ]. 
Moreover, thousands of copies of interrelated splices from a unit gene 
are found in the brain [ 19 ]. Another limitation of proteomics is that 
neuropsychiatric disorders are multigenic by nature and include the 
interaction of multiple proteins that are expressed spatially on a small 
scale and are in different stages of the psychological disorder [ 20 ]. The 
solubility of surface hydrophobic proteins, limited separation range 
of proteins and limited detection sensitivity of analytical techniques 
also pose a challenge in the proteomics ﬁeld [ 21 ]. Herein, unlike ge- 
nomic studies that can study tens of thousands of gene expressions 
at a time, proteomic studies can only study a few thousands at a time 
[ 22 ]. The main challenge in animal studies pertains to sample collec- 
tion and preparation, where sample size is negligible and thus may 
not be suitable for proteomics analysis. This problem is translated in 
the brain regions such as the hippocampus and the thalamus which 
are limited in size, hard to obtain in signiﬁcant amounts and, in ad- 
dition to all other brain regions, are susceptible to degradation by 
various cellular proteases and sample collection variations [ 23 ]. 
1.4. Proteomic tools and methodology 
The basic steps of any proteomic method include extracting pro- 
teins from tissues, applying a separation / fractionation technique to 
transform complex protein mixtures into ones of fewer components, 
analyzing the sample via an advanced technique such as MS and 
processing the obtained data by comparing the results with those 
found in the databases or literature [ 24 , 25 ]. A schematic of the gen- 
eral methodology followed by the proteomic studies discussed in this 
paper is depicted in Fig. 1 . 
To address the issue of protein abundance as a limiting step in the 
proteomic approach, fractionation steps are essential before starting 
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Fig. 1. Schematic of the general procedures followed by the proteomic studies discussed in this paper (1) 2D-DIGE technique, (2) iTRAQ technique and (3) Shotgun analysis. 
the MS analysis [ 26 ]. Even highly abundant serum proteins may be ex- 
hausted using afﬁnity chromatography-based techniques such as 2D 
polyacrylamide gel electrophoresis (2D-PAGE) and high performance 
liquid chromatography (HPLC) [ 27 ]. 
MS is an important method in proteomic analysis. It can be com- 
menced by either electrospray ionization (ESI) or matrix-assisted 
laser desorption / ionization (MALDI) methods, which are both “soft 
ionization” techniques that transfer proteins into the gaseous state 
without too much fragmentation [ 14 , 28 ]. For simple peptide sam- 
ples, examination with MALDI-time of ﬂight (TOF) MS is acceptable, 
whereas, for more complex systems, separation using HPLC column 
joined to ESI MS systems is recommended [ 29 ]. Surface enhanced 
laser desorption / ionization (SELDI) MS is based on retaining proteins 
through protein chip systems with pre-activated surfaces via antibod- 
ies, receptors, ionic or hydrophobic materials followed by ionization 
and MS detection [ 30 ]. 
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Another quantitative method is iTRAQ, also known as isobaric la- 
beling for relative and absolute quantitation. iTRAQ is a procedure 
in which samples are tagged disjointedly with isobaric labels before 
being blended and introduced to liquid chromatography and tandem 
MS (LC / MS / MS) [ 31 ]. The isobaric labels comprise an abundance re- 
porter ion, which is directly related to the protein quantity they are 
associated with [ 32 ]. 
Another approach is to use shotgun proteomics as an analytical 
method, which allows for the identiﬁcation and quantitation of hun- 
dreds of complex sample proteins [ 33 ]. Proteins are ﬁrst digested by 
enzymes such as trypsin and are then sent to MS system for analysis 
[ 34 ]. Some advantages of this method include: basic protein analysis, 
high molecular weight protein analysis ( > 120 kDa) and low abun- 
dance protein detection [ 35 ]. 
Finally, two-dimensional difference gel electrophoresis (2D-DIGE) 
is among the basic traditional multidimensional methods, which en- 
ables the visual assessment of proteins. In 2D-DIGE, proteins extracted 
from two or three samples are tagged directly with different ﬂuores- 
cent dyes such as Cy2, Cy3 and Cy5 before being separated by 2-DE 
[ 36 ]. The dynamic changes in protein levels related to various states 
can be easily detected, thus generating sensitive and reproducible re- 
sults [ 37 ]. Some disadvantages associated with this method are the 
solubility of the hydrophobic protein surface, the restricted dynamic 
range and the use of amine-reactive DIGE dyes for labeling [ 21 ]. 
Post MS analysis and data acquisition, spectral library tools are 
used to compare MS scans to those stored in these libraries. In the 
medical ﬁeld, there is still a shortage of information in protein and 
peptide databases for identiﬁcation, functional and structural pro- 
teomic analysis [ 38 ]. Thus, there is a need to continue developing 
competent tools for proteomic analysis. 
Below is a review of recent studies in the ﬁeld of neuroproteomics 
pertaining to the effect of drug abuse and addiction on various brain 
regions. Table 1 summarizes the major neuroproteomic studies dis- 
cussed. 
2. Cocaine neuroproteomics 
2.1. General overview 
Cocaine is globally known as one of the most dangerous illicit 
drugs with high addictive properties, and it is believed that over 1.6 
million Americans are currently using cocaine, including males and 
females aged 12 years or older (SAMSHA, 2013). Cocaine misuse is 
an intricate behavior that is inﬂuenced by genetic and environmental 
factors, which in turn reﬂects different levels of cocaine abuse vul- 
nerability among humans and animal models. It is a chronic mental 
disorder in which the addict compulsively consumes drugs irrespec- 
tive of the consequences, leading to the progression of drug seeking 
behavior [ 40 ]. Even though drug addiction studies have indicated that 
cocaine ’ s oxidative metabolites are among the causes behind its neg- 
ative side effects [ 59 ], the biochemical pathways behind urging an 
individual to seek and abuse cocaine, and other drugs, are still to be 
fully elucidated. 
Importantly, many studies have demonstrated that the NAc invig- 
orates the euphoric effects of cocaine [ 39 , 42,43 ]. More speciﬁcally, 
several studies have indicated that cocaine up-regulates the cyclic 
AMP (cAMP) pathway [ 60 ], glutamate [ 61 ], activator protein 1 fam- 
ily members [ 62 ], dopamine (DA) [ 63 ], γ-aminobutyric acid (GABA), 
growth factors, opiate receptors, metabolism and cytoskeletal ele- 
ments present in the NAc [ 64 –67 ]. 
To assess the effects of the different psychoactive drugs in animal 
models, researchers employ a number of behavioral testing among 
which is the conditioned place preference (CPP) test. In this model, 
an animal is placed in a speciﬁc environment that is paired with 
the administration of a certain drug, followed by an assessment of 
the animal ’ s preference towards that environment. Thus, an animal 
spending an increased time in the drug-associated environment cor- 
relates with the positive rewarding properties of the drug under study 
[ 68 ]. In other words, this method can simulate drug addiction with 
its different stages from attainment to extinction and reinstatement. 
2.2. Neuroproteomics in rodent models 
In one study by Del Castillo et al., rats underwent cocaine-induced 
CPP (15 mg / kg intraperitoneally (ip)) and were separated into two 
subpopulations according to whether drug addiction was extin- 
guished (E) or not extinguished (NE) [ 39 ]. Following an extra ad- 
ministration of either cocaine (COC) or saline (SAL), 2D-DIGE and 
MALDI-TOF MS were used to proﬁle the proteome of the rats ’ NAc. 
When comparing E SAL rats to NE SAL rats, NE SAL rats had a de- 
creased expression of the three metabolic proteins (ATP synthase al- 
pha subunit, transketolase and fumarate hydratase) and an increased 
expression of NADH dehydrogenase [ubiquinone] ﬂavoprotein 2 (ND- 
FUS2) and glutathione S-transferase omega-1 (GSTO1). In contrast 
to this study, Guindalini et al. found that there is an increased glu- 
tathione transferase activity due to a genetic polymorphism detected 
more frequently in cocaine users compared to healthy individuals 
[ 59 ]. Thereafter, when comparing E SAL to E COC, Del Castillo et 
al. identiﬁed three out of six proteins: an up-regulated NDUFA10 
and a down-regulated fumarate hydratase and dihydropyrimidinase- 
related protein 2 (DRP2), where DRP2 has been previously discovered 
to aid in axon elongation when phosphorylated [ 69 ]. Remarkably, the 
down-regulation of fumarate hydratase in E COC and NE SAL, when 
compared to E SAL, suggested that a single dose of cocaine might rein- 
state the cocaine-seeking behavior in rats via a mechanism pertaining 
to fumarate hydratase. Also, when comparing NE COC to E COC, the 
proteins ATP5a1, NDUFA10, peroxiredoxin-5 (PRDX5), and nucleo- 
side diphosphate kinase B were decreased while the 60 kDa heat 
shock protein (HSP60) was increased. Finally, comparing NE COC to 
NE SAL also yielded a difference in protein expression. The identiﬁed 
proteins were peroxiredoxin-2 (PRDX2), (PRDX5), GSTO1, NDUFS2, α- 
synuclein, phosphatidylethanolamine-binding protein 1 (PEBP1) and 
fumarylacetoacetate hydrolase domain containing 2A (FAH2A). Of in- 
terest is a previous study performed by Mash et al., which established 
that α-synuclein blood level reduction via cocaine diminishes drug 
craving intensity [ 70 ]. Moreover, in a recent study by Ryan et al. it 
was demonstrated that α-synuclein can also be involved in decreas- 
ing dopaminergic transmission [ 71 ]. Finally, Goumon et al. found that 
PEBP1, a Raf kinase inhibitor, is expressed in the limbic system [ 72 ]. 
In another study conducted by Guan and Guan, rat medial pre- 
frontal cortex (mPFC) was evaluated following repeated cocaine ex- 
posure (10 mg / kg ip) [ 40 ]. Proteins were separated via 2DE, iden- 
tiﬁed and quantiﬁed via MALDI-TOF MS and tandem TOF / TOF MS. 
Two groups of rats (either being injected with cocaine or saline) un- 
derwent CPP for 8 days to discard rats that spend more than 500 s 
in the same chamber, followed by a CPP test on the ninth day to 
evaluate cocaine-induced reward effects. Using 2DE, they found that 
50 spots were signiﬁcantly up-regulated and 21 were signiﬁcantly 
down-regulated in the group of cocaine treated rats. Moreover, Guan 
and Guan conﬁrmed the presence of that same trend of some differ- 
entially expressed proteins via western blotting, which added credi- 
bility to their work. Even though neuroproteomics is a very sensitive 
and accurate method, it would still be more favorable to conﬁrm the 
obtained results by performing traditional techniques such as west- 
ern blot, ELISA and PCR. Furthermore, in addition to the metabolic 
proteins, more than 27% of the total mapped proteins of this study 
were related to actin cytoskeleton regulation where there was an in- 
crease in stathmin and tubulin alpha 8 chains but a decrease in the 
tubulin alpha 3 chain. Thus, the ﬁndings of this study show that co- 
caine addiction may lead to structural and functional impairments in 
the mPFC by disrupting axonal transport where Duncan et al. have 
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Table 1 
List of recent neuroproteomics studies on the effect of cocaine, METH and MDMA on different brain regions. 
Drug Model Drug dosage Brain region 
Proteomic 
method 
Number of 
identiﬁed 
differen- 
tially 
expressed 
proteins Functional domains of proteins Reference 
Cocaine Rats 15 mg / kg for 3 days NAc 2-DE and 
MALDI-TOF MS 
14 Mitochondrial, dopaminergic 
transmission, anti-oxidant, cell 
structure and cell signaling 
Del 
Castillo et 
al. [ 39 ] 
Rats 10 mg / kg of chronic 
administration 
mPFC 2-DE and MS 71 Metabolism, cell structure, 
anti-oxidants, cell signaling, 
synaptic proteins, detoxiﬁcation, 
structure regulatory proteins, cell 
cycle regulatory proteins, 
proteinase, ligase, transferase, 
gene regulatory protein, sensor 
protein and others 
Guan and 
Guan [ 40 ] 
Rats 10 days of 40 
infusions / day of 
1.5 mg / kg per infusion 
mPFC 2D-DIGE and 
MALDI-TOF / TOF 
MS 
20 Cell structure and metabolism Lull et al. 
[ 22 ] 
Rats 2 weeks of self 
administration of 
0.05 ml of 0.2 mg 
cocaine with each lever 
press 
NAc iTRAQ 42 Cytoskeleton, synaptic, cell 
signaling, channels, receptors, 
transporters, metabolism and cell 
adhesion 
Reissner 
et al. [ 41 ] 
Juvenile Vervet 
Monkeys 
14 days of chronic 
administration of 2 or 
4 mg / kg / day 
OFC 2D-DIGE and 
iTRAQ 
40 Cytoskeleton, metabolism, cell 
cycle, synaptic, protein folding, 
cell adhesion and cell signaling 
Olausson 
et al. [ 31 ] 
Rhesus Monkeys Chronic administration 
of 0.5 mg / kg 
NAc 2D-DIGE and 
MALDI-TOF / TOF 
MS 
18 Cell structure, metabolism and 
cell signaling 
Tannu et 
al. [ 42 ] 
Post-mortem 
human samples 
of cocaine 
overdose victims 
N / A NAc 2D-DIGE and 
MALDI-TOF MS 
15 Cell structure, synaptic plasticity, 
signal transduction, 
mitochondrial and metabolic 
Tannu et 
al. [ 43 ] 
Methamphetamine Rats Acute administration of 
1 mg / kg 
Striatum 2DE and 
MALDI-TOF MS 
26 Mitochondrial, metabolic, protein 
degradation and cell structure 
Iwazaki 
et al. [ 44 ] 
Rats Saline injection ﬁrst 
2 days, followed by 
METH (1 mg / kg) on 
3rd day and then 
4 mg / kg for 10 days 
Striatum 2-DE and 
MALDI-TOF MS 
32 Metabolism, cytoskeleton, 
oxidative, mitochondrial, synaptic 
and apoptosis 
Iwazaki 
et al. [ 45 ] 
Rats Acute administration of 
1 mg / kg 
Amygdala 2DE and 
MALDI-TOF MS 
48 Metabolism, cellular 
cytoskeleton, oxidative stress and 
apoptosis 
Iwazaki 
et al. [ 46 ] 
Rats 8 injections of 
15 mg / kg Hippocampus, 
striatum and 
frontal cortex 
2DE and 
MALDI-TOF / TOF 
MS 
30 Oxidative stress, protein 
degradation, scavengers, 
mitochondrial, metabolism and 
apoptosis 
Li et al. 
[ 47 ] 
Rats and PC12 Acute administration of 
15 mg / kg 
Striatum 2DE and 
MALDI-TOF / TOF 
MS and SILAC 
30 Nitrated 
proteins 
Cytoskeleton, cdk5 activation, 
ribosome function, protein 
nitration and apoptosis 
Zhang et 
al. [ 48 ] 
Rats Acute administration of 
10, 20 or 40 mg / kg 
Cortex and 
hippocampus 
SDS-PAGE AII-spectrin 
and tau 
Cytoskeleton Warren et 
al . [ 49 ] 
Rats Acute administration of 
40 mg / kg 
Cortex CAX-1D-SDS- 
PAGE and RPLC 
MS / MS 
82 Oxidative stress, synaptic 
transmission and cell death 
Kobeissy 
et al. [ 50 ] 
Rats 3 discontinuous 
injections of 1 mg / kg 
NAc, PFC, 
cingulate 
cortex, 
striatum and 
hippocampus 
2-DE and 
MALDI-TOF MS 
27 Cytoskeleton, cell signaling, 
transport, endocytosis and 
exocytosis 
Yang et 
al. [ 51 ] 
Rat 8 injections of 1 mg / kg Frontal 
cortex 
2-DE and 
MS / MS 
47 
Cytosolic 
and 42 
membrane- 
bound 
proteins 
Metabolism, redox regulation, 
protein degradation, cellular 
growth, synaptic function and 
cytoskeleton 
Faure et 
al. [ 52 ] 
Mice 3 injections of 
10 mg / kg 
Striatum and 
susbtantia 
nigra 
2-DE and 
Reverse 
phase-nano- 
HPLC-ESI-MS / 
MS 
5 Mitochondrial and protein 
degradation 
Liao et al. 
[ 53 ] 
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Table 1 
Continued 
Drug Model Drug dosage Brain region 
Proteomic 
method 
Number of 
identiﬁed 
differen- 
tially 
expressed 
proteins Functional domains of proteins Reference 
MDMA Rats 5 mg / kg for 10 days 
Hippocampus 
SDS-PAGE and 
MALDI-TOF MS 
8 Intracellular signaling, 
neuroplasticity, transport and 
cytoskeleton 
van 
Nieuwen- 
huijzen 
[ 54 ] 
Rats Administration of 10, 
20 and 30 mg / kg 
Striatum N / A N / A Mitochondrial Puerta et 
al. [ 55 ] 
Rats 100 mg / kg of DSP-4 
and 4 administrations 
of 10 mg / kg MDMA 
Hippocampus 
SDS-PAGE N / A SERT and VMAT-2 Biezonski 
and 
Meyer 
[ 56 ] 
Rats 2 oral administration of 
10 mg / kg 
Liver 2-DE and 
Reverse phase- 
nano-LC-tandem 
MS 
33 Oxidation and nitration Moon et 
al. [ 57 ] 
Rats 2 oral administration of 
10 mg / kg 
Liver 2-DE and 
Reverse phase- 
nano-LC-tandem 
MS 
22 Cell signaling, apoptosis, 
anti-oxidant, metabolism, 
mitochondrial and calcium 
regulation 
Upreti et 
al. [ 58 ] 
shown that stathmin is important in maintaining microtubule in- 
tegrity [ 73 ]. Other up-regulated proteins include the ERK3 protein, a 
protein that has proved to be disruptive of signal transduction and 
neuronal morphology [ 74 ] and dimethylarginine dimethylaminohy- 
drolase 1 (DDAH1), which was shown to affect nitric oxide signal 
transduction and plays a role in cocaine CPP memory reconsolidation 
[ 75 ]. 
It is noteworthy that calcium-binding protein P22-like (CHP) was 
increased, which means that calcineurin may have been inhibited. 
This inhibition was previously shown to modulate synapsin 1 pro- 
tein [ 76 ] that is located on the presynaptic nerve terminals and in- 
volved in DA release post psychostimulant administration [ 77 ]. Other 
up-regulated proteins related to synaptic plasticity and trafﬁcking, 
identiﬁed by Guan and Guan, include neuroligin 4, neurexin beta 
1, synaptotagmin 15, butyrophilin 1 and CB1 cannabinoid receptor- 
interacting protein (CNRIP1). All of these results suggest that cocaine 
may lead to neuro-adaptations of drug-associated synaptic plasticity, 
morphological and structural changes in the mPFC and can in turn 
contribute to the start and augmentation of drug seeking and abuse 
[ 78 ]. 
Taken together, it can be noticed that even though Del Castillo et 
al. and Guan and Guan identiﬁed similar proteins in both the NAc and 
mPFC, respectively, each brain region differentially expressed a spe- 
ciﬁc subunit of each of those proteins. For example, cocaine induced 
a differential expression of ATP synthase beta subunit, NDFUS11 and 
the ATP synthase lipid binding protein in the mPFC. In contrast, the 
same drug induced a differential expression of the ATP synthase alpha 
subunit and NDFUS2 in the NAc. 
In another study by Reissner et al., NAc tissues were analyzed in a 
rat model of cocaine administration (intra-jugular 40 infusions / day of 
1.5 mg / kg per infusion for 10 days) using iTRAQ proteomic platform, 
thus identifying 42 proteins of the postsynaptic density-enriched sub- 
fraction that are differentially expressed [ 41 ]. Focus was particularly 
given to the up-regulated AKAP79 / 150 protein. This protein was char- 
acterized by Wong and Scott, as a postsynaptic density scaffolding 
protein that conﬁnes signaling molecules to the synapse [ 79 ]. Over- 
all, the ﬁndings of Reissner et al. demonstrated that AKAP proteins 
contribute to cocaine relapse vulnerability by endorsing ampliﬁed 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) re- 
ceptor surface expression in the NAc. 
Another point to highlight in the general study of cocaine addic- 
tion is the time it takes for the drug effects to wear off. This topic was 
evaluated in a study by Lull et al. who assessed proteomic changes in 
the mPFC of rats receiving cocaine for 10 days, followed by a compar- 
ison between na ¨ıve rats and rats with one day and 100-day cocaine 
abstinence [ 22 ]. They found that there are some protein changes due 
to drug administration that persist up to the 100 days of abstinence 
but other proteins do not. These short-term up-regulated proteins 
include synapse-associated proteins that are involved in vesicle ex- 
ocytosis, dynamin-1, alpha-internexin and neuroﬁlament medium. 
Even though the up-regulation does not persist, the effect of these 
proteins ’ increased expression may last and can be translated into 
persistent neuronal remodeling even after the protein level goes back 
to normal. It was also found that there are some protein changes 
that are not due to drug administration but take place during absti- 
nence. Like most studies, the proteins involved were mostly related 
to metabolism and cell structure [ 22 ]. 
2.3. Neuroproteomics in non-human primate models 
One way in which iTRAQ method was made even more efﬁcient 
was in an experiment done on the orbitofrontal cortex (OFC) of non- 
human primates (14 days of chronic administration of 2 or 4 mg / kg of 
cocaine per day) [ 31 ]. In those experiments Olausson et al. isolated the 
synaptic compartment of the OFC: synaptoneurosomes, making the 
preparation less complex and more focused on synaptic proteins and 
function. Through 2D-DIGE and iTRAQ, they conﬁrmed their previous 
ﬁndings on changes in alpha actin, beta tubulin, HSP70, trisphosphate 
isomerase, ATP synthase and glyceraldehyde-3-phosphate dehydro- 
genase, and other proteins. Similar to other studies, Olausson et al. 
found that there was a change in the expression of proteins related 
to cytoskeletal, metabolic and signaling functions. Importantly, this 
study showed that animal models other than rodents could be em- 
ployed in proteomic studies. 
Another study by Tannu et al. performed on rhesus monkeys 
examined the effect of chronic cocaine administration (0.5 mg / kg 
intra-venous (IV)) on protein expression and phosphorylation in the 
NAc via 2D-DIGE and 2DGE / phosphoprotein gel staining, respectively 
[ 42 ]. The latter were also analyzed by MALDI TOF / TOF MS. The pro- 
teins identiﬁed here were also related to metabolism / mitochondrial 
function, cell structure, synaptic plasticity and signal transduction. 
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Those proteins included the up-regulated glial ﬁbrillary acidic pro- 
tein (GFAP), protein kinase C isoform, syntaxin binding protein 3, 
mitochondrial-related proteins and adenylate kinase isoenzyme 5, 
and the down-regulated neural and non-neural speciﬁc enolase and 
beta-soluble N-ethylmaleimide-sensitive factor attachment protein. 
Furthermore, 15 phosphoproteins were also identiﬁed in the NAc, 
indicating their importance in the functional proteome. The study 
also revealed an increased expression of brain-type aldolase, GABA-A 
receptor associated protein 1, glutathione S-transferase and 14-3-3 
gamma protein, and a decreased expression of PRDX2 isoform b, beta 
actin, guanine deaminase, Rab GDP dissociation inhibitor and other 
mitochondrial proteins [ 42 ]. 
2.4. Neuroproteomics in post-mortem human samples 
In order to detect the proteomic changes that take place in the hu- 
man brain more accurately, one study examined the effect of chronic 
cocaine abuse on the human NAc, using 2D-DIGE [ 43 ]. Tannu et al. 
extracted the NAc from frozen brain tissue of 10 cocaine overdose 
(COD) abusers and 10 controls, and only analyzed the cytosolic frac- 
tions by MALDI TOF / TOF MS. Out of the 1407 spots that were found, 18 
spots were differentially expressed and were identiﬁed as 15 proteins 
via peptide mass ﬁngerprinting (PMF). One of the up-regulated pro- 
tein was liprin α3, a postsynaptically expressed protein, responsible 
for transporting AMPA and N-methyl- d -aspartate (NMDA) receptor 
vesicles along microtubules, which in turn have a role in mediating 
cocaine relapse in the NAc [ 43 ]. Some of the differentially regulated 
proteins found by Tannu et al. included PRDX2, which was shown to 
be a neuronal H 2 O 2 regulator [ 80 ], neural speciﬁc enolase, ATP syn- 
thase beta chain, and the cell structure proteins TUB2, desmoplakin, 
GFAP and chaperonin. In addition, parvalbumin, which was shown to 
regulate intracellular calcium [ 81 ], was shown to be down-regulated 
in the study by Tannu et al. Moreover, the change in protein expres- 
sion may be either due to cocaine itself or due to the up-regulated 
GluR receptors, which may increase calcium ﬂux and cause oxidative 
stress [ 43 ]. 
Even though the different models of cocaine usage included dif- 
ferent species, there were still some common differentially expressed 
proteins among them. These proteins include ATP synthase, PRDX2, 
actin, tubulin, HSP, GFAP, kinases, neural speciﬁc enolase and glu- 
tathione S-transferase. This overlap among different species suggests 
that the signaling pathways induced by cocaine are quite similar 
among different organisms and this suggests that we are able to have 
an idea about the effect of cocaine on the human brain by ﬁnding the 
effect on animal brains. Moreover, even though there were proteins 
that did not overlap between all organisms, the affected proteins in all 
models belonged to the same ﬁelds such as metabolism, cell structure 
and cell signaling. 
3. Methamphetamine neuroproteomics 
3.1. General overview 
Methamphetamine belongs to the amphetamine family of drugs 
and is one of the most abused drugs worldwide [ 82 ] with an estimated 
number of 440,000 abusers in the US alone (SAMHSA, 2013). Repeated 
exposure to METH leads to sensitization, which is an increased behav- 
ioral response to subsequent exposures [ 83 ] due to chronically altered 
neuronal plasticity [ 44 ]. The negative consequences of METH abuse 
have been extensively studied with its most prominent effect being 
the destruction of dopaminergic neurons that project from the sub- 
stantia nigra to the striatum [ 84 ]. High dosages of METH may lead to 
fatal seizures, cerebrovascular hemorrhages, hyperthermia and death 
[ 85 ] while withdrawal symptoms include depression, psychomotor 
dysfunctions and psychosis [ 86 ]. The major neuropsychiatric conse- 
quences include memory problems, motor skills and attention deﬁcits 
and poor decision-making, which may be attributed to the destruc- 
tion of the dopaminergic fronto-striato-cortical neurons [ 87 ]. METH 
is so potent that it can cross the blood–brain-barrier and the placental 
barrier and cause long-term effects on the brain and fetal develop- 
ment [ 88 ]. 
METH induces neuropathological changes in the brain through 
several mechanisms. These include decreasing the dopamine trans- 
porter (DAT) level in the dorsolateral prefrontal cortex, orbitofrontal 
cortex, caudate putamen [ 89 ] and basal ganglia [ 90 ]. Furthermore, 
DA is thought to be released from storage vesicles into the cytoplasm 
and extracellular matrix, leading to the production of reactive oxygen 
species [ 44 ] and quinine by-products, which are associated with lipid 
peroxidation at the monoaminergic terminals [ 91 ]. METH adminis- 
tration can also induce neurotoxicity at the glutamatergic terminals 
[ 92 ] and in different brain regions such as the striatum, parietal cor- 
tex, neocortex and somatosensory cortex [ 93 ]. Decrease in cortical 
gray matter [ 94 ] and serotonin transporters of orbitofrontal and cin- 
gulate cortices have also been documented [ 95 ]. METH abusers also 
have a decreased level of the neuronal marker N-acetylaspartate and 
an increased level of the glial marker myoinositol [ 96 ] as well as in- 
creased microglial activation [ 97 ]. METH can also induce apoptotic 
and necrotic pathways via glutamate release, leading to nitric oxide 
formation [ 98 ] and calcium-dependent calpain activation [ 99 ]. In ad- 
dition to that, METH can induce the activation of caspase-3, 9 and 12 
and the increase in expression of GRP78 / BiP and of C / Ebp homol- 
ogous protein that are involved in apoptosis [ 100 ]. Likewise, it also 
up-regulates the Bax, Bad and Bid pro-apoptotic genes and down- 
regulates the Bcl-2 and Bcl-xL anti-apoptotic genes [ 101 ]. 
Like cocaine, there are many studies that investigated proteomic 
changes in different brain regions and at different dosages, as a result 
of METH administration. Also, it has been shown that METH prompts 
changes in proteins associated with metabolism / mitochondrial func- 
tion, cytoskeleton, synaptic plasticity, cell signaling and protein 
degradation. 
3.2. Neuroproteomics on rat striatum 
Iwazaki et al. investigated the effect of a single, low dose (1 mg / kg 
ip) of METH on protein expression in the striatum of rats [ 44 ]. Using 
2DE-based proteomics they found 36 differentially expressed pro- 
teins in the striatum, of which 26 were increased and 10 decreased 
in METH-treated rats compared to saline-treated rats. When METH 
enters the mitochondria, it decreases ATP-synthase activity and thus 
raises the pH of the inner membrane matrix and reduces the mem- 
brane potential control, which disrupts normal cellular functioning 
[ 44 ]. The proteins related to mitochondrial function that were dif- 
ferentially expressed included: phosphoglycerate kinase 1, pyruvate 
kinase, ATP synthase F (1) beta chain, alpha enolase, isocitrate de- 
hydrogenase [NAD] subunit alpha, DLP1 splice variant 3 (related to 
apoptosis), cystatin beta (related to apoptosis), creatine kinase and 
lactate dehydrogenase that are markers of cellular injury. In addi- 
tion to those proteins, Iwazaki et al. found that there was an in- 
crease in dihydrolipoamide dehydrogenase, an enzyme involved in 
the Kreb ’ s cycle, age-related activity and oxidative inhibition [ 102 ], 
and voltage-dependent anion-selective channel protein 1, which is 
involved in mitochondrial pore formation to release cytochrome C 
in apoptosis [ 103 ]. As for the metabolic-related proteins that were 
differentially expressed in the striatum, there were PRDX 2 and 
5 and the glucose-regulated protein precursor. Moreover, the pro- 
teins related to the ubiquitin–proteasome pathway included: protea- 
some RN3 subunit, ubiquinol-cytochrome C reductase core protein I 
and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1). UCH-L1 was 
found to be involved in germ cell and neuronal apoptosis [ 104 ] and 
in the degenerative process of Alzheimer ’ s and Parkinson ’ s diseases 
[ 105 , 106 ]. Finally, Iwazaki et al. also found that there was a change in 
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the expression of N-tropomodulin, GDI alpha and beta actin, indicat- 
ing cytoskeletal modiﬁcation without morphological changes even at 
a single low, non-toxic level of METH administration (1 mg / kg) [ 44 ]. 
Iwazaki et al. performed another study to determine the proteomic 
proﬁle of rat striatum following METH-induced behavioral sensiti- 
zation (2 day saline injection, followed by 1 mg / kg METH on 3rd 
day and then 4 mg / kg for 10 days ip) [ 45 ]. Using MALDI-TOF MS, 
they found 42 differentially expressed proteins, out of which 31 were 
identiﬁed. Some of the identiﬁed proteins include synapsin II, hip- 
pocalcin, DRP2, PEBP, adenylyl cyclase-associated protein 1 (CAP1) 
and synaptosomal-associated protein 25 (SNAP-25). Studies suggest 
that the synapsin family can modulate vesicle trafﬁcking [ 107 ] and 
aide in docking the vesicles at the active zone [ 108 ]. Moreover, hip- 
pocalcin is a neuronal calcium sensor and it has been shown to be 
neuroprotective against calcium-induced cell death [ 109 ]. 
A noteworthy work by Liao et al. studied the effects of METH- 
induced nigrostriatal dopaminergic neurotoxicity in a mouse model 
(3 injections of 10 mg / kg via infusion cannula aimed at the striatum 
and substantia nigra) [ 110 ]. Similar to previous studies, α-synuclein, 
F-actin capping protein B subunit, ATPase, peroxidase and ubiquitin 
UCH-L1 were shown to be differentially expressed [ 110 ]. 
3.3. Neuroproteomics on rat amygdala 
Another study by Iwazaki et al. studied the effect of acute and 
chronic METH administration on the amygdala of rats (acute: ip saline 
ﬁrst 2 days, 1 mg / kg on day 3; chronic: ip saline ﬁrst 2 days, 1 mg / kg 
on day 3, 4 mg / kg from day 4 to 14 and 1 mg / kg on day 22) [ 46 ]. 
Using MALDI-TOF, 43 and 48 proteins were identiﬁed in METH sen- 
sitized rats and rats with acute METH administration, respectively. 
Interestingly, they found that there were only three differentially 
expressed proteins in common between the amygdala and the stria- 
tum, and those were TP1 protein, synapsin-2b and tropomyosin. This 
means that these two brain regions react differently to METH ad- 
ministration. Intriguingly, chronic and acute METH administrations 
created two different patterns of protein level in the amygdala with 
an overlap of only nine proteins. Those proteins were LDH-B, Tpi1, 
Gapd protein, phosphoglycerate mutase B, fructose-bisphosphate al- 
dolase C, glutathione S-transferase (GSTP), synapsin-2b and PRDX 5 
and 6. But all in all, with all these variations, the identiﬁed proteins 
were mostly involved in metabolism, cellular cytoskeleton, oxidative 
stress and apoptosis [ 46 ]. 
3.4. Neuroproteomics on multiple rat brain regions and traumatic 
brain injury 
In 2008, Li et al. studied the proteomic proﬁle of the hippocam- 
pus, striatum and frontal cortex (8 ip injections of 15 mg / kg at 12 h 
intervals) [ 47 ]. They found 14, 12 and 4 differentially expressed pro- 
teins in the striatum, hippocampus and frontal cortex, respectively. 
Even though each brain region had a different pattern of protein 
change, two or three different brain regions shared some proteins. 
Herein, these brain regions may have followed similar pathways of 
METH-induced neurotoxicity, different from those followed by the 
amygdala. The common proteins were ATP synthase D chain, α- 
synuclein, mitochondrial Cu −Zn superoxide dismutase (SOD1), stath- 
min 1, ubiquitin-conjugating enzyme E2N, and DDAH1. It is thought 
that α-synuclein, E2N and SOD1 may have been up-regulated as a 
protective mechanism [ 47 ]. Indeed, α-synuclein has been found to 
interact with DA-derived oxidative species to prevent oxidative dam- 
age [ 111 ], while E2N has been found to be involved in degrading the 
harmful nitrated and oxidatively modiﬁed proteins that result from 
METH administration [ 47 ]. As for the SOD1, it can scavenge for ex- 
ogenous and endogenous superoxide ions [ 112 ]. 
Even though the exact mechanism by which METH induces an in- 
crease in nitric oxide production is unknown [ 113 ], one hypothesis is 
that METH induces the activation of the DDAH1 / ADMA (asymmetric 
dimethylated l -arginine) / NOS (nitric oxide synthase) pathway [ 48 ]. 
In a recent study, Zhang et al. found that administering a DDAH1 in- 
hibitor, Nx-(2-methoxyethyl)-arginine (L-257), to METH-treated rats 
would decrease the nitric oxide production, meaning that METH acts 
through the DDAH1 / ADMA / NOS pathway [ 48 ]. In this same study, 
it was found that there was an increase in 30 nitrated proteins, in- 
cluding tropomodulin 1 and 2, in both rats and PC12 cells (rats: 8 
ip injections of 15 mg / kg at 12 h intervals; PC12: 2 mM). PC12 are 
pheochromocytoma cells derived from the rat adrenal medulla, and 
can develop characteristics of catecholaminergic sympathetic neu- 
rons when treated with nerve growth factor [ 114 ]. Stable isotope 
labeling with amino acids in cell culture (SILAC) was employed for 
detecting nitrated proteins in METH-treated PC12 because, according 
to Zhang et al., 2-DE is not as efﬁcient for that job. Zhang et al. were 
interested in the increased expression of the nitrated protein GSTP1 
and the decreased expression of the normal GSTP1, which is known 
for its protective role against oxidative stress. The nitration of GSTP1 
has been shown to subsequently activate the p25 / p35 / cdk5 path- 
way which will in turn impose oxidative stress [ 115 ]. Taking that into 
consideration, Zhang et al. elucidated a potential mechanism through 
which METH can induce an increase in NO production via the DDAH1 / 
ADMA / NOS pathway and the p25 / p35 / cdk5 pathway. 
The deleterious effects of METH on the CNS have also been com- 
pared to TBI. In a study by Warren et al., the effect of acute ip METH 
administration (10, 20 or 40 mg / kg) on rat hippocampus and cor- 
tex was analyzed and compared to the changes following TBI [ 49 ]. 
Using SDS-PAGE, Warren et al. found that there was an increase in 
the breakdown products of MAP- τ and αII-spectrin (SBDP120 and 
SBDP150). The presence of these products suggests neuronal cell 
death [ 116 , 117 ]. Warren et al. found that the severity of neurotoxic- 
ity was almost equal to TBI when a dosage of 40 mg / kg of METH was 
administered. They suggested that a single METH administration me- 
diates neurotoxicity via calpain-induced proteolysis in the cortex, and 
calpain and caspase-induced proteolysis in the hippocampus, leading 
to cytoskeletal changes in neurons [ 49 ]. 
After acute METH administration (ip 40 mg / kg), Kobeissy et al. 
found 82 differentially expressed proteins in the rat cortex, of which 
42 were up-regulated and 40 were down-regulated [ 50 ]. The identi- 
ﬁed proteins were involved in oxidative stress, synaptic transmission 
and cell death. The up-regulated proteins included UCH-L1, UCH-L3, 
synapsin I protein and microtubule-associated protein light chain 3 
(LC3). LC3 is attached to autophagosomes [ 118 ], so in other words, 
METH is inducing the formation of autophagic vesicles. These vesi- 
cles are able to engulf oxidized and degraded proteins that may kill 
the neurons [ 119 ]. On the other hand, down-regulated proteins that 
Kobeissy et al. found included SOD1, MKK1, PEBP1, collapsin response 
mediator protein 2 (CRMP2) and the F-actin scaffolding protein that 
has been proven to be a neuronal cytoskeleton stabilizer [ 110 ]. Both 
PEBP1 and CRMP2 were found to be substrates of the calpain pathway 
[ 120 , 121 ], and since METH acts through this pathway, it accounts for 
the decreased level of these substrates. Kobeissy et al. concluded that 
there was a similarity in the proteomic changes taking place after 
both TBI and acute METH treatment, meaning that there could be 
common neurobiological events leading to the long-term neurologi- 
cal and neuropsychiatric effects [ 50 ]. 
Additionally, Yang et al. found that a positive CPP test was estab- 
lished after three discontinuous (ip) injections of 1 mg / kg of METH in 
rats [ 51 ]. Protein proﬁles in the NAc, PFC, cingulate cortex, striatum 
and hippocampus were then compared. They identiﬁed 27 differ- 
entially expressed proteins that were related to the same functions 
as the proteins found by other studies. Proteins related to the cy- 
toskeleton included LMOa7, G protein b-subunit, neuroﬁlament and 
Neogenin; while the proteins related to cell signaling included N-myc 
downstream-regulated gene 2, G protein b-subunit soluble guanylyl 
cyclase, GDP dissociation inhibitor 1 and 14-3-3 protein. The 14-3-3 
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protein is functionally important in altering behavior following sub- 
chronic METH treatment, activating protein kinase C (PKC), Raf-1 in 
the signal transduction mitogen activated protein kinase (MAPK) cas- 
cade, and tryptophan and tyrosine hydroxylases [ 122 ]. 
In addition, it has also been shown that PKC is an important me- 
diator of behavioral sensitization to METH [ 123 ]. In the study of Yang 
et al., the expression of the 14-3-3 protein was decreased in the hip- 
pocampus only. So, there exists a discrepancy where Kobeissy et al. 
found a decrease in PEBP1 in the rat cortex while Yang et al. found a de- 
crease in the 14-3-3 protein, which is a Raf activator, in the hippocam- 
pus. This means that the cortex may be activating the PKC pathway, 
thus augmenting behavioral sensitization, while the hippocampus is 
doing the exact opposite. Identiﬁed proteins related to transport, en- 
docytosis and exocytosis included proﬁlin-2 and syntaxin. Yang et 
al. suggested that the alteration of Proﬁlin-2 expression might lead to 
increased post-synaptic endocytosis in the striatum and NAc, thus, in- 
ducing a decrease in intracellular calcium and dopamine D2 receptor 
internalization [ 51 ]. Interestingly, intracellular calcium is involved in 
developing sensitization [ 124 ], so there is another discrepancy here 
where a decrease in intracellular calcium would mean that there is 
an attenuation of behavioral sensitization to METH. This discrepancy 
is further maintained in a study by Borlongan et al. that showed that 
decreasing intracellular calcium via cyclosporine-A would increase 
METH-induced locomotor behavior [ 125 ]. 
In addition to using different models, drugs and dosages and exam- 
ining different brain regions, one should also take into consideration 
identifying proteins as cytosolic or membrane bound because these 
factors may inﬂuence the proteomic proﬁle. Unfortunately, there is 
only one study that categorized proteins into cytosolic and membrane 
bound. In this 2009 study, Faure et al. examined the proteomic pro- 
ﬁles of rat frontal cortex following eight METH injections (ip, 1 mg / kg) 
[ 52 ]. There were 47 cytosolic and 42 membrane proteins that were 
differentially expressed, which were associated with metabolism, re- 
dox regulation, protein degradation, cellular growth, synaptic func- 
tion and cytoskeletal modiﬁcations. 
3.5. Neuroproteomics on rat striatum and olfactory bulb 
In a recent study from our lab, escalating chronic model of 
methamphetamine was assessed for differential proteomic proﬁle in 
two rat brain regions: the olfactory bulb and the hippocampus (data 
not published). METH was injected (ip) for 2 weeks, starting from 
0.5 mg / kg and ending with 8 mg / kg on the 14th day. To identify dif- 
ferentially expressed proteins, we applied LC–ESI-MS / MS, followed 
by multiple reaction monitoring (MRM) LC–MS / MS for conﬁrmation. 
There were 11 differentially expressed proteins in the hippocampus, 
including the down-regulated spectrin alpha chain non-erythrocytic 
1 (SPTN1) and the up-regulated synaptic vesicle glycoprotein 2A 
(SV2A), as well as the myelin proteolipid protein (MYPR), brain acid 
soluble protein 1 (BASP1), V-type proton ATPase subunit B brain iso- 
form (VATB2) and glutathione S-transferase alpha 3 (GSTA3). More- 
over, we found seven differentially expressed proteins in the olfactory 
bulb, including the down-regulated alpha-2-HS-glycoprotein (FETUA) 
and the up-regulated 6-phosphofructokinase type C (K6PP), as well as 
the CNRIP1, Secernin-1 (SCRN1), and the guanine nucleotide-binding 
protein G(i) subunit alpha 1 and 2 (GNAI1 and GNAI2). SV2A is in- 
volved in regulating synaptic vesicle transport [ 126 ] but not in the 
release, storage and uptake of neurotransmitters [ 127 ]. According 
to Hanaya et al., decrease in SV2A levels may interfere in GABAer- 
gic functions and induce epileptic seizures and sclerotic changes 
throughout the hippocampus [ 128 ]. On the other hand, non-erythroid 
spectrin is involved in regulating neuritogenesis [ 129 ], assembling 
the Nodes of Ranvier and stabilizing sodium channels [ 130 ]. GNAI is 
involved in intracellular signaling, where the alpha subunit is speciﬁ- 
cally responsible for transiently binding GTP and GDP [ 131 ]. Further- 
more, FETUA was found to be structurally similar to TGF-B receptor 
[ 132 ] and was able to interfere with insulin receptor signaling [ 133 ]. 
Moreover, secernin-1, was found to play an integral role in regulating 
exocytosis from peritoneal mast cells and affecting mast cell sen- 
sitivity to stimulation with calcium [ 134 ]. Secernin-1 has also been 
implicated as a biomarker for gastric and colon cancer [ 135 ], and more 
recently, synovial sarcoma [ 136 ]. 
Neurosystems biology analysis of differential proteins was per- 
formed utilizing PANTHER (protein analysis through evolutionary re- 
lationships) software and Pathway Studio software to construct an 
interaction map, exhibiting direct and indirect pathways of proteins, 
which highlighted the involvement of metabolic, neuroprotective, cy- 
toskeletal, cell signaling and transport pathways as shown in Fig. 2 . In 
this work, 35 differential proteins were identiﬁed in the hippocampus 
brain region (20 down-regulated vs. 15 up-regulated proteins) while 
(9 down-regulated vs. 13 up-regulated proteins) in the olfactory bulb 
(data presentation pending publishing). A subset of these proteins 
were validated in both brain regions and were used to assess the pro- 
tein interaction map and the biological process involved, as shown in 
Fig. 2 . 
4. MDMA neuroproteomics 
4.1. General overview 
Today, the abusive intake of 3,4- 
methylenedioxymethamphetamine, also known as MDMA or 
more commonly known as Ecstasy, is an escalating issue both in the 
US and many parts of the world, making it a public health problem 
[ 137 –139 ]. MDMA usage has been decreasing globally, except for 
Europe that has witnessed an increase to reach a number of about 2 
million users in the past year. The acute exposure to MDMA is known 
to cause damage to organs such as brain, heart, liver, and kidneys. 
Such damages can be deadly, causing myocardial infarction usually 
accompanied with hyperthermia, hypertension, and tachycardia, 
which precede disseminated intravascular coagulation, rhabdomy- 
olysis, multiple organ failure and, eventually, death [ 140 ]. When 
administered to humans and non-humans, MDMA damaged sero- 
tonin cell bodies and nerve terminals [ 141 ] and induced neuronal loss 
in the nigrostriatal dopaminergic terminals and the substantia nigra 
compacta [ 142 ]. MDMA also increased the reactive oxygen species in 
the monoaminergic systems [ 143 ] and decreased vesicular DA trans- 
port [ 144 ]. Not to mention that MDMA metabolism produced 3,4- 
methylenedioxyamphetamine (MDA), 3,4-dihydroxyamphetamine 
(HHA) and 3,4-dihydroxymethamphetamine (HHMA) that can form 
thioether metabolites or quinone compounds, which produce free 
radicals [ 141 ]. 
Although many studies have proven that the use of MDMA does, in 
fact, cause liver damage, the underlying mechanisms were unknown 
until recently. Many studies in the ﬁeld of proteomics, such as those 
done by Moon et al. and Upreti et al., have touched upon the mecha- 
nism behind the induced damage [ 57,58 ]. Using comparative 2-DE in 
the analysis of the proteins in the liver that undergo modiﬁcation after 
acute MDMA administration, they were able to have an idea about the 
mechanisms underlying liver damage. The studies mentioned below 
aim to explain the toxicity mechanisms of MDMA, including those 
found in liver tissue. It is believed that the mechanisms taking place 
in hepatocytes also apply to other cells and tissues such as the brain 
and kidney [ 57 ]. 
4.2. Proteomic studies on the liver 
After orally administering 10 mg / kg of MDMA on day 1 and 2, 
Moon et al. and Upreti et al. observed a great difference between the 
protein expression in controls and MDMA-exposed rat livers. There 
were around 33 proteins identiﬁed by Moon et al. and around 22 by 
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Fig. 2. Global interaction proteome: associating biological processes and altered METH-induced proteome. The altered nodes (genes) and edges (gene relationships) are described in 
the ﬁgure. The node color indicates gene regulation where purple nodes reﬂect up-regulation while green nodes reﬂect down-regulation. The gray-colored genes are not identiﬁed 
as differentially expressed genes in our experiment but are integrated into the computationally generated networks on the basis of third party connectors that highlight the 
relation to the identiﬁed network. Furthermore, yellow boxes indicate identiﬁed biological processes. The pathway includes interacting proteins of metabolism, neuroprotection, 
cytoskeleton, cell signaling and transport. 
Upreti et al. The 22 differentially expressed proteins identiﬁed by Up- 
reti et al. were oxidatively modiﬁed proteins belonging to the domains 
of metabolism, calcium-binding proteins and antioxidant defensive 
enzymes [ 58 ]. The 33 differentially expressed proteins identiﬁed by 
Moon et al. belonged to the domains of energy supply, oxidative phos- 
phorylation, mitochondrial electron transport, anti-oxidative defense 
system, fatty acid and intermediary metabolism, molecular chaperon 
proteins and voltage-dependent calcium proteins [ 57 ]. Moon et al. 
identiﬁed other spots as fragments of full-length proteins; such spots 
represented proteins of smaller molecular weight (e.g. 26–30 kDa). 
The fragmentation of these proteins may have been due to either 
the increased susceptibility of mitochondrial proteins to proteasomal 
degradations under oxidative stress [ 145 , 146 ] or simply the sponta- 
neous fragmentation of oxidized proteins [ 147 ]. 
It is the quinone metabolites of MDMA, produced via cytochrome 
P450-catalyzed metabolism, that are important in MDMA-induced 
organ damage, while the direct administration of MDMA to brain tis- 
sue does not cause any tissue damage [ 148 , 149 ]. The main reason for 
this is that these metabolites produce oxidative and nitrosative stress 
by the inhibition of the mitochondrial respiratory chain [ 150 –152 ]. 
However, the way these metabolites work on the suppression of the 
mitochondrial respiratory chain is still unknown. In addition, MDMA 
metabolites work on decreasing the level of reduced glutathione, 
which is protective against a broad range of metabolite-related free 
radicals of several toxic compounds. The presence of both reactive 
oxygen and reactive nitrogen species can create a more potent oxi- 
dant peroxynitrite (ONOO −), which may be the cause of irreversible 
tissue and cell damage [ 153 ]. 
More mitochondrial proteins such as acetyl-CoA dehydrogenase, 
UDP-glucose pyrophosphorylase 2, HSP86, HSP75, and cytochrome 
P450 11B1 (CYP11B1) were also found [ 57 ]. Moon et al. showed ox- 
idative patterns of both CYP11B1 and CYP19A1, however there was 
no oxidation of CYP2D6, CYP1A2, and CYP3A4, which are involved in 
MDMA metabolism [ 154 ]. This is most probably because of their low 
expression levels [ 57 ]. Moon et al. and Upreti et al. have speculated 
that the mechanism behind protein inactivation by MDMA is due to 
oxidative stress caused by the metabolites of MDMA, and the direct 
binding of metabolites to these proteins [ 57,58 ]. 
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4.3. Neuroproteomic studies on the brain 
In a study performed by Van Nieuwenhuijzen on rat hippocam- 
pus, animals were chronically administered MDMA for 10 days (ip 
5 mg / kg) and were ﬁnally sacriﬁced 8 weeks post-administration 
[ 54 ]. MDMA administration provoked residual changes in eight pro- 
teins involved in intracellular signaling (C-crk, 14-3-3 protein epsilon 
and adenyl cyclase), neuroplasticity (neuronal pentraxin-1), trans- 
port (alpha-soluble NSF-attachment protein and V-type proton AT- 
Pase subunit F) and cytoskeletal function (tubulin folding cofactor B 
and tropomyosin alpha 3 chain). 
In another study by Puerta et al., the administration of an in- 
creasing dose of MDMA (10, 20, 30 mg / kg (ip) injected every 2 h) 
resulted in a noticeable decline in mitochondrial complex I activity 
[ 55 ]. MDMA-treated mice showed production of O 2 - or O 2 -derived 
oxidants in their corpus striatum, 3 h following MDMA treatment. 
After 3 and 6 h of MDMA exposure, a noticeable decline in aconitase 
activity (metabolic function) was also noted. The study found that ad- 
ministration of NG-nitro-l-arginine (l-NNA), a nitric oxide synthase 
inhibitor, has signiﬁcantly served as a neuro-protective agent against 
DA loss [ 55 ]. Moreover, the addition of lipoic acid inhibited the for- 
mation of reactive oxygen species but did not reverse the MDMA- 
induced inhibition of complex I. This suggests that a complex I inhibi- 
tion happens early in MDMA neurotoxicity. Additionally, Puerta et al. 
treated the mice with MDMA and the Parkinsonian toxin 1-methyl- 
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). They co-administered 
the non-toxic MDMA treatments and it resulted in a substantial long- 
term decline of striatal DA concentration. However, the addition of 
MPTP did not result in increasing the effect of MDMA, and thus they 
concluded that DA depletion was the result of MDMA alone [ 55 ]. 
In a second study, researchers aimed at ﬁnding the effects of 
MDMA on the hippocampus of DSP-4 / MDMA-treated rats and mice 
(ip injection of 100 mg / kg DSP-4 and 4 sc injection of 10 mg / kg 
MDMA) [ 56 ]. DSP-4 is a neurotoxin that affects noradrenergic neurons 
by depleting their noradrenaline [ 155 ]. After 2 weeks of continuous 
MDMA exposure, Biezonski and Meyer found no signiﬁcant changes 
in the expression levels of vesicular monoamine transporter 2 pro- 
tein (VMAT-2) in MDMA-treated animals compared to DSP-4 / saline 
controls. However, serotonin transporter (SERT) levels were substan- 
tially declined in all MDMA-treated groups. This means that although 
amounts of SERT did decline, there was no terminal induced loss [ 56 ]. 
Furthermore, Biezonski and Meyer found a declined gene expression 
of SERT and VMAT-2, showing that DSP-4 may regulate serotonergic 
neurons without affecting distal axotomy. 
Finally, unlike the case of cocaine and METH, there are only a 
few studies that were done to assess proteomic proﬁle changes post 
MDMA exposure. Of interest are the MDMA studies that focused on 
MDMA distribution throughout the body [ 156 ] and its effects on dif- 
ferent organs other than the brain [ 157 –159 ]. Even though the num- 
ber of studies on the effect of MDMA on the brain is negligible, the 
effect of MDMA on other organ systems may still give us a clue about 
what is happening in the brain. 
5. Conclusion 
To sum up, the aim behind proteomic studies is to assess the effect 
of drugs on humans and try to ﬁnd therapeutic methods to treat addic- 
tion and abuse. Unfortunately, there are only few proteomic studies 
on drug abuse. Moreover, most studies have used animal models to 
proﬁle protein expression following drug administration; but protein 
expression in animals might be different from protein expression in 
humans. Moreover, few studies have been conducted on postmortem 
human samples, whether drug abusers or controls, and they might 
not be very reliable in representing drug effects in living humans; 
that is because the people from whom the samples were taken might 
have had a certain neurological or neurodegenerative disease that 
could have affected the protein expression in the brain; however, 
this situation is not exclusive to neuroproteomics studies on drug 
abuse models. Moreover, the cause of death in those people was not 
mentioned in several studies; those people may have had a TBI for 
example, or any other malady that might have directly or indirectly 
caused their death and in turn affected their brain proteomic proﬁle 
much more than the drugs that they were taking. In some studies, 
drug overdose was mentioned as the cause of death; however, over- 
dose may lead to different direct causes of death such as a stroke or 
heart attack or any other organ failure. Accordingly, the altered brain 
proteomic proﬁle could be more due to the direct cause of death and 
less due to the effect of the drug on the brain. 
Additionally, even though cocaine, METH and MDMA are chem- 
ically and structurally different, they appeared to induce common 
pathways and cause similar cellular changes. The pathways were 
mainly involved in metabolism / mitochondrial function, cell signal- 
ing, cytoskeleton, protein modiﬁcation and degradation, cell death 
and synaptic plasticity. Unfortunately, all of these studies were not 
able to detect proteins that are vital for drug addiction such as GT- 
Pases, phosphatases, kinases and neurotransmitter receptors because 
they are too scarce and hard to separate when compared to the other 
abundant proteins that are being detected. Relevant receptors such 
as GABA, DA and glutamate receptors were not detected in these pro- 
teomic studies even though they play an essential role in mediating 
the effects of drugs at the genetic and proteomic level. 
Even though many studies used the same experimental design 
and analysis method, each got a different protein expression pro- 
ﬁle. This could be attributed to different experimental methodologies 
and models, experimental errors, instrumentation and insensitive MS 
readings. This necessitates further studies to ascertain that the differ- 
ential identiﬁed proteins are truly involved in mediating the effects of 
drug abuse. Thus, better model selection and improved sample prepa- 
ration may also be needed for detecting a wider range of proteins. 
The realm of proteomics is still in its beginning and it has started 
to bring about many possibilities and even more questions to answer 
in many domains. This ﬁeld could be further incorporated into the 
clinical setting where the level of drug addiction and the severity of 
drug-induced damage could be easily assessed. Nowadays, medicine 
is heading towards a point of care system where we are trying to 
develop handheld devices (such as those that measure blood glucose 
in diabetic patients) that are both fast and accurate in measuring 
blood-borne substances that help in assessing the clinical situation of 
a patient. We may not be far from ﬁnally attaining such a neuropro- 
teomic handheld device to measure the level of expression of certain 
neuronal proteins (in the blood, CSF or maybe even brain tissue) and 
in turn assess the effect of any drug on the brain of the patient at 
hand. Yet, what remains to do is to further study the intricate brain 
functions and delve into the most speciﬁc cell signaling pathways 
that are directly and indirectly being affected by the drug in question. 
Only then would we understand the true effect of each drug on the 
brain and target the right protein or proteomic expression proﬁle in 
our quest of assessing the drug ’ s effect on the brain and accordingly 
establish new therapeutic modalities. 
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